Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sirnaomics and China Partner File to Begin China Trials of siRNA Drug

publication date: Jan 6, 2015
Sirnaomics, a US-China biopharma, together with its partner Guangzhou Xiangxue Pharma, have filed with the CFDA to begin human clinical trials of STP705, an anti-fibrosis short-interfering RNA (siRNA) drug. The trial, which will be conducted simultaneously in the US and China, will test whether STP705 prevents and treats human skin hypertrophic scars. Sirnaomics said STP705 is the first siRNA product to file a China Class 1.1 IND, a class reserved for novel drugs not previously approved anywhere in the world. More details....

Stock Symbol: (SHE: 300147)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here